64Cu-NOTA-曲妥珠单抗PET显像在乳腺癌患者的初步临床试验
该初步临床试验在7例乳腺癌患者中评估了64Cu-NOTA-Trastuzumab的体内分布与安全性,注射296 MBq后于1、24、48小时行PET显像。结果显示HER2阳性肿瘤SUVmax相对高于HER2阴性肿瘤,未见相关不良事件,有效剂量为2.96 mSv。
要点
- 64Cu-NOTA-Trastuzumab在HER2表达肿瘤中显示特异性摄取。
- HER2阳性肿瘤48小时SUVmax高于HER2阴性肿瘤。
- 注射296 MBq后有效剂量2.96 mSv,未见相关不良事件。
核心结论
- 64Cu-NOTA-Trastuzumab在HER2表达肿瘤中显示特异性摄取,可作为乳腺癌患者HER2肿瘤状态可行且安全的监测工具。
研究设计与样本
- 初步临床试验纳入7例乳腺癌患者,注射296 MBq的64Cu-NOTA-Trastuzumab后于1、24、48小时行PET显像。
- 评估原发肿瘤及转移灶的SUVmax,以及血液池、肝、肾、肌肉、脾、膀胱、肺和骨等器官的SUVmean。
- 采用OLINDA/EXM软件计算内照射剂量,并根据给药后1个月内不良反应及安全相关问题评估安全性。
主要发现
- 各器官总体SUVmean值随时间呈负相关。
- 肝脏平均SUVmean在注射后1、24、48小时分别为5.3 ± 0.7、4.8 ± 0.6、4.4 ± 0.5。
- 血液平均SUVmean在注射后1、24、48小时分别为13.1 ± 0.9、9.1 ± 1.2、7.1 ± 1.9。
- 注射后48小时HER2阳性肿瘤SUVmax为8.6 ± 5.1,HER2阴性肿瘤为5.2 ± 2.8。
- HER2阳性肿瘤的肿瘤-本底比高于HER2阴性肿瘤。
关键数值与推荐
- 注射296 MBq的64Cu-NOTA-Trastuzumab计算有效剂量为2.96 mSv。
- 最高吸收剂量位于肝脏(0.076 mGy/MBq),其次为脾(0.063 mGy/MBq)、肾(0.044 mGy/MBq)和心壁(0.044 mGy/MBq)。
- 未报告与64Cu-NOTA-Trastuzumab相关的不良事件。
临床怎么用
- 可用于乳腺癌患者HER2肿瘤状态的PET显像监测,需关注肝脏和脾脏的吸收剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The purpose of this study was to evaluate both the biodistribution and safety of 64Cu-1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)-Trastuzumab, a novel 64Cu-labeled positron emission tomography (PET) tracer for human epidermal growth factor receptor 2 (HER2) in patients with breast cancer. METHODS: PET images at 1, 24, and 48 h after 296 MBq of 64Cu-NOTA-Trastuzumab injection were obtained from seven patients with breast cancer. Both the primary tumors' and metastatic lesions' maximum standardized uptake value (SUVmax) was evaluated. The mean SUVmax (SUVmean) was evaluated in the other organs, including the blood pool, liver, kidney, muscle, spleen, bladder, and the lungs, as well as the bones. Moreover, the internal radiation dosimetry was calculated using the OLINDA/EXM software. Safety was assessed based on feedback regarding adverse reactions and safety-related issues within 1 month after 64Cu-NOTA-Trastuzumab administration. RESULTS: 64Cu-NOTA-Trastuzumab PET images showed that the overall SUVmean values in each organ negatively correlated with time. The liver's average SUVmean values were measured at 5.3 ± 0.7, 4.8 ± 0.6, and 4.4 ± 0.5 on 1 h, 24 h, and 48 h after injection, respectively. The average SUVmean blood values were measured at 13.1 ± 0.9, 9.1 ± 1.2, and 7.1 ± 1.9 on 1 h, 24 h, and 48 h after injection, respectively. The SUVmax of HER2-positive tumors was relatively higher than HER2-negative tumors (8.6 ± 5.1 and 5.2 ± 2.8 on 48 h after injection, respectively). Tumor-to-background ratios were higher in the HER2-positive tumors than in the HER2-negative tumors. No adverse events related to 64Cu-NOTA-Trastuzumab were reported. The calculated effective dose with a 296 MBq injection of 64Cu-NOTA-Trastuzumab was 2.96 mSv. The highest absorbed dose was observed in the liver (0.076 mGy/MBq), followed by the spleen (0.063 mGy/MBq), kidney (0.044 mGy/MBq), and heart wall (0.044 mGy/MBq). CONCLUSIONS: 64Cu-NOTA-Trastuzumab showed a specific uptake at the HER2-expressing tumors, thus making it a feasible and safe monitoring tool of HER2 tumor status in patients with breast cancer. TRIAL REGISTRATION: CRIS, KCT0002790. Registered 02 February 2018, https://cris.nih.go.kr.
引用
- Lee I, Lim I, Byun BH, et al. A preliminary clinical trial to evaluate 64Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer. EJNMMI Res. 2021. PMID: 33475899. doi:10.1186/s13550-021-00746-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。